Immune tolerance after liver transplant
Part of Digestive system clinical trials.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and had a living donor liver transplant between 1 and 20 years ago.
- Your donor and you match on at least 6 out of 12 key immune system markers (HLA typing).
- A recent liver biopsy shows no signs of rejection.
- You can stay within 3 hours of UCLA Medical Center for the first 3 months.
- You are not pregnant and agree to use birth control for 12 months if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.